A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation. SGO Annual Meeting. Abstr. 136; presented March 25, 2014 - Coleman, R L; Sill, M; Aghajanian, C
et al.